JP5751519B2 - 白血球の血管外遊出またはガン細胞の成長及び／もしくは転移を抑制するポリペプチドまたはその融合蛋白質 - Google Patents

白血球の血管外遊出またはガン細胞の成長及び／もしくは転移を抑制するポリペプチドまたはその融合蛋白質 Download PDF

Info

Publication number
JP5751519B2
JP5751519B2 JP2012535105A JP2012535105A JP5751519B2 JP 5751519 B2 JP5751519 B2 JP 5751519B2 JP 2012535105 A JP2012535105 A JP 2012535105A JP 2012535105 A JP2012535105 A JP 2012535105A JP 5751519 B2 JP5751519 B2 JP 5751519B2
Authority
JP
Japan
Prior art keywords
polypeptide
cells
seq
present
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012535105A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013507954A (ja
JP2013507954A5 (enExample
Inventor
ハン，チャンヒ
イ，ギョンジン
イ，ソンヒ
ジュ，ヒョンミ
Original Assignee
スパデリクサー インコーポレイテッド
スパデリクサー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スパデリクサー インコーポレイテッド, スパデリクサー インコーポレイテッド filed Critical スパデリクサー インコーポレイテッド
Publication of JP2013507954A publication Critical patent/JP2013507954A/ja
Publication of JP2013507954A5 publication Critical patent/JP2013507954A5/ja
Application granted granted Critical
Publication of JP5751519B2 publication Critical patent/JP5751519B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2012535105A 2009-10-23 2010-08-24 白血球の血管外遊出またはガン細胞の成長及び／もしくは転移を抑制するポリペプチドまたはその融合蛋白質 Active JP5751519B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020090101003A KR101061017B1 (ko) 2009-10-23 2009-10-23 암세포의 성장 및/또는 전이 억제용 약학 조성물
KR10-2009-0101003 2009-10-23
PCT/KR2010/005619 WO2011049289A2 (ko) 2009-10-23 2010-08-24 백혈구의 혈관외유출 또는 암세포의 성장 및/또는 전이를 억제하는 폴리펩타이드 또는 그의 융합 단백질

Publications (3)

Publication Number Publication Date
JP2013507954A JP2013507954A (ja) 2013-03-07
JP2013507954A5 JP2013507954A5 (enExample) 2014-08-07
JP5751519B2 true JP5751519B2 (ja) 2015-07-22

Family

ID=43900764

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012535105A Active JP5751519B2 (ja) 2009-10-23 2010-08-24 白血球の血管外遊出またはガン細胞の成長及び／もしくは転移を抑制するポリペプチドまたはその融合蛋白質

Country Status (6)

Country Link
US (1) US8530421B2 (enExample)
EP (2) EP2491944A4 (enExample)
JP (1) JP5751519B2 (enExample)
KR (1) KR101061017B1 (enExample)
CN (1) CN102711792A (enExample)
WO (1) WO2011049289A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0689637B2 (ja) 1990-08-28 1994-11-09 株式会社荏原製作所 トンネル微気圧波低減装置

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101644982B1 (ko) * 2015-07-23 2016-08-02 주식회사 엔솔바이오사이언스 신규 펩타이드 및 그 용도
CN118806792A (zh) * 2016-03-02 2024-10-22 高等教育联邦系统-匹兹堡大学 结合基质的纳米囊泡及其用途
US20200095296A1 (en) * 2017-06-05 2020-03-26 The Trustees Of Columbia University In The City Of New York Use of peptides as biomarkers in the diagnosis, confirmation and treatment of a neurological disorder and tcr and/or hla immunoprofiling in neurodegenerative disease
KR102268921B1 (ko) * 2019-12-10 2021-06-23 강원대학교산학협력단 p53을 활성화하는 펩타이드를 포함하는 조성물
WO2021118212A1 (ko) * 2019-12-11 2021-06-17 강원대학교산학협력단 P53과 foxo4의 상호작용을 억제시키는 펩타이드를 포함하는 약학 조성물
KR20230033097A (ko) * 2021-08-27 2023-03-08 (주)티카로스 기능이 강화된 신규 키메라 항원 수용체(car)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
CA2305681C (en) * 1997-09-30 2013-01-08 Peviva Ab Apoptosis-related compounds and their use
WO2000032235A1 (de) * 1998-11-26 2000-06-08 Pentapharm Ag Transportsystemkonjugate
US6451969B1 (en) * 1999-01-15 2002-09-17 The Burnham Institute Methods for inhibiting tumor metastasis, and peptides useful therfor
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
CA2402530C (en) * 2000-03-13 2014-01-14 Cornell Research Foundation, Inc. Blocking leukocyte emigration and inflammation by interfering with cd99
CH694935A5 (de) * 2000-07-26 2005-09-30 Straumann Holding Ag Oberflaechenmodifizierte Implantate.
US7460960B2 (en) * 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
BR0313638A (pt) * 2002-08-21 2005-06-21 Merck Patent Ges Mit Berschron Epìtopos de células t na enterotoxina b em estafilococos
US7385027B2 (en) * 2003-01-07 2008-06-10 University Of Kentucky Research Foundation Membrane-permeable peptide capable of calpain inhibition
WO2005074986A2 (en) * 2004-02-10 2005-08-18 Genobiotix Aps Bioactive species capable of interfering with a microbial toxin-antitoxin complex and methods for evaluation and use of said bioactive species
CN101437539B (zh) 2005-07-05 2013-10-02 康奈尔研究基金会（有限公司） 通过干扰cd99l2阻断白细胞迁出和炎症
US8207128B2 (en) * 2005-09-28 2012-06-26 Supadelixir Inc. Polypeptide inhibiting transmigration of leukocytes or growth and/or metastasis of cancer cells, and fusion protein thereof
KR100793947B1 (ko) * 2006-06-30 2008-01-16 강원대학교산학협력단 암세포의 성장 및 전이 억제 활성을 갖는 폴리펩타이드또는 그의 융합 단백질
KR100793949B1 (ko) * 2006-07-19 2008-01-16 강원대학교산학협력단 염증 질환의 예방 또는 치료 활성을 갖는 폴리펩타이드또는 그의 융합 단백질
KR100941678B1 (ko) * 2007-12-17 2010-02-12 강원대학교산학협력단 암세포의 전이 억제 활성을 갖는 폴리펩타이드 또는 그의융합 단백질
KR101074005B1 (ko) * 2009-02-26 2011-10-17 재단법인춘천바이오산업진흥원 백혈구의 혈관외유출 억제 활성을 갖는 폴리펩타이드 또는 그의 융합 단백질

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0689637B2 (ja) 1990-08-28 1994-11-09 株式会社荏原製作所 トンネル微気圧波低減装置

Also Published As

Publication number Publication date
US20120245091A1 (en) 2012-09-27
WO2011049289A2 (ko) 2011-04-28
JP2013507954A (ja) 2013-03-07
EP2491944A2 (en) 2012-08-29
EP2692353A3 (en) 2014-03-26
EP2491944A4 (en) 2013-09-11
CN102711792A (zh) 2012-10-03
US8530421B2 (en) 2013-09-10
KR20110044374A (ko) 2011-04-29
EP2692353A2 (en) 2014-02-05
WO2011049289A3 (ko) 2011-07-14
KR101061017B1 (ko) 2011-08-31

Similar Documents

Publication Publication Date Title
JP5751519B2 (ja) 白血球の血管外遊出またはガン細胞の成長及び／もしくは転移を抑制するポリペプチドまたはその融合蛋白質
CA2689296C (en) Polypeptide inhibitors of hsp27 kinase and uses therefor
KR101997757B1 (ko) 악액질 예방 또는 치료용 조성물
CA2854289C (en) Dpp-4 inhibitor
CA2741302C (en) Mapkap kinase inhibitor polypeptide for treating or preventing adhesions
AU2011298556B2 (en) Use of interleukin-22 in treating viral hepatitis
WO2011149964A9 (en) Methods for treating or preventing vascular graft failure
JPWO2013183494A1 (ja) 好中球活性化に起因する疾患の治療薬、治療方法及び検査方法
EP3079711A1 (en) Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
CN103897038A (zh) 一种肿瘤抑制多肽及用途
ES2627816T3 (es) Variantes del pro-dominio de tace como inhibidor de TNF-a y su uso médico
JP3030386B2 (ja) 抗ガン剤
AU2020234373B2 (en) Novel peptide and use thereof
JP2017510635A (ja) オストレオリシン、機能的に関連したその変異体、オストレオリシンを含む抽出物、及びそれらの使用
JP2007508823A (ja) 新規な熱ショックタンパク質２０関連ポリペプチドおよびその使用
CN106659764B (zh) 环状鞘脂激活蛋白原肽及其用途
WO2017054831A1 (en) Use of human derived immunosuppressive proteins and peptides as medicaments
JPWO2016104436A1 (ja) サイトカインストーム抑制剤
JP2005504516A (ja) ＨＡｂ１８Ｇ／ＣＤ１４７における拮抗剤及びその応用
CN101356190B (zh) 用于抑制pf4和rantes相互作用的拮抗剂
JP5982394B2 (ja) ＭＭＰ基質で連結したβｉｇ−ｈ３断片ペプチド及びそのリウマチ性関節炎予防及び治療用途
WO2012027170A1 (en) Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
CN115605502A (zh) 用于预防或治疗纤维化疾病的重组融合蛋白
KR101260421B1 (ko) Ｃｔｌａ４ 및 ｉｌ２１ｒ 을 포함하는 융합 단백질 및 이를 포함하는 관절염 예방 및 치료용 조성물
KR101233073B1 (ko) 백혈구의 혈관외유출 억제 활성 및 암세포의 전이 억제 활성을 갖는 펩타이드를 포함하는 약학 조성물

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141106

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150428

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150508

R150 Certificate of patent or registration of utility model

Ref document number: 5751519

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250